Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
MilliporeSigma
64 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
API
Enhanced Solubility through API Processing: Salt and Cocrystal Formation
PAO-05-23-CL-04
International Markets
In what international markets do you anticipate significant developments in the near future?
PAO-01-23-RT-02
Disruptive Technology
What do you view as the most disruptive or transformational technology or development on the horizon?
PAO-01-23-RT-01
3D Printing
Advancing Extrusion-Based 3D Printing for Drug Production
PAO-11-022-CL-14
Sweeteners
High-Intensity Sweeteners for Taste Optimization
PAO-11-022-CL-12
Sustainability
What is your plan to build a more sustainable business practice in the coming years?
PAO-10-022--RT-01
Real-Time Monitoring
Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing
PAO-09-022-CL-08
Manufacturing Investment
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
PR-M09-22-02
Lipid Excipients
Regulatory Considerations for Lipid Excipients
PAO-07-022-CL-04
Excipient Quality Assurance
Assuring Excipient Quality for Parenteral Products
Biomanufacturing
Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds
PAO-07-022-CL-02
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
PAO-06-022--RT-01
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
O-06-022--RT-01
Advanced Excipients
How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs
PAO-04-022-CL-07
Bioprocessing
Better Bioprocessing Efficiency Through Centralized Orchestration
PAO-03-022-CL-23
Excipients
Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations
PAO-01-22-CL-02
Leadership
Q: What’s the key to being a leader in the industry?
PAO-03-022-RT-02
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
PAO-03-022-RT-01
Facility Acquisition
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
PR-M02-22-20
Business Development
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth
PR-M02-22-03
Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation
Personalized and Precision Medicine
Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?
PAO-12-21-RT-01
Therapeutic Progress
Q: For what therapeutic area do you think we will see the greatest progress in the coming years?
PAO-12-21-RT-02
2021 Roundup: The Year of Cell and Gene Therapy
1
3
»
